People · Operator
Named in public records as an officer, director or promoter · active 2013–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurana Pharmaceuticals, Inc. | — | Biotechnology | Series C | $45.7M | $1.7B | 2013 |
Daniel F. Becker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel F. Becker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David F Hale | 1 | 16 |
| Kathleen D. Scott | 1 | 5 |
| Joshua F. Richardson | 1 | 1 |
| David F. Kabakoff | 1 | 1 |
| Craig F. Thompson | 1 | 1 |
| Brian F. Dorsey | 1 | 1 |
| Randall D. Kaye, M.D. | 1 | 1 |
| Alex F. Zisson | 1 | 1 |
| Judy Caron | 1 | 1 |
| Jeffrey Raser | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.